nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC18A2—telencephalic ventricle—brain cancer	0.0544	0.134	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalic ventricle—brain cancer	0.0411	0.101	CbGeAlD
Lisdexamfetamine—SLC18A2—ganglion—brain cancer	0.0338	0.0834	CbGeAlD
Lisdexamfetamine—SLC6A3—ganglion—brain cancer	0.0256	0.0631	CbGeAlD
Lisdexamfetamine—SLC6A2—ganglion—brain cancer	0.0207	0.0509	CbGeAlD
Lisdexamfetamine—SLC6A3—hindbrain—brain cancer	0.0194	0.0479	CbGeAlD
Lisdexamfetamine—SLC18A2—brainstem—brain cancer	0.0147	0.0363	CbGeAlD
Lisdexamfetamine—Visual disturbance—Lomustine—brain cancer	0.0138	0.0252	CcSEcCtD
Lisdexamfetamine—Digestion impaired—Hydroxyurea—brain cancer	0.0133	0.0242	CcSEcCtD
Lisdexamfetamine—SLC18A2—telencephalon—brain cancer	0.0131	0.0322	CbGeAlD
Lisdexamfetamine—SLC6A3—brainstem—brain cancer	0.0111	0.0274	CbGeAlD
Lisdexamfetamine—Digestion impaired—Temozolomide—brain cancer	0.0104	0.0189	CcSEcCtD
Lisdexamfetamine—SLC18A2—medulla oblongata—brain cancer	0.0103	0.0253	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalon—brain cancer	0.00988	0.0243	CbGeAlD
Lisdexamfetamine—SLC18A2—midbrain—brain cancer	0.00938	0.0231	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—brain cancer	0.00898	0.0221	CbGeAlD
Lisdexamfetamine—Visual impairment—Lomustine—brain cancer	0.00875	0.0159	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—OTX2—brain cancer	0.00843	0.188	CbGpPWpGaD
Lisdexamfetamine—Diplopia—Procarbazine—brain cancer	0.00833	0.0152	CcSEcCtD
Lisdexamfetamine—SLC18A2—endocrine gland—brain cancer	0.00824	0.0203	CbGeAlD
Lisdexamfetamine—ADRA1B—head—brain cancer	0.00821	0.0202	CbGeAlD
Lisdexamfetamine—SLC18A2—head—brain cancer	0.00813	0.02	CbGeAlD
Lisdexamfetamine—SLC6A2—telencephalon—brain cancer	0.00797	0.0196	CbGeAlD
Lisdexamfetamine—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.0075	0.0136	CcSEcCtD
Lisdexamfetamine—ADRA1B—central nervous system—brain cancer	0.00749	0.0185	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—brain cancer	0.00742	0.0183	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—brain cancer	0.00725	0.0179	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—brain cancer	0.00709	0.0175	CbGeAlD
Lisdexamfetamine—SLC6A3—spinal cord—brain cancer	0.00692	0.0171	CbGeAlD
Lisdexamfetamine—SLC6A2—gonad—brain cancer	0.00665	0.0164	CbGeAlD
Lisdexamfetamine—SLC6A2—medulla oblongata—brain cancer	0.00626	0.0154	CbGeAlD
Lisdexamfetamine—SLC6A3—head—brain cancer	0.00615	0.0152	CbGeAlD
Lisdexamfetamine—Anorexia—Lomustine—brain cancer	0.00615	0.0112	CcSEcCtD
Lisdexamfetamine—ADRA1B—brain—brain cancer	0.00595	0.0147	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—brain cancer	0.00589	0.0145	CbGeAlD
Lisdexamfetamine—Body temperature increased—Carboplatin—brain cancer	0.00583	0.0106	CcSEcCtD
Lisdexamfetamine—Hallucination—Procarbazine—brain cancer	0.00573	0.0104	CcSEcCtD
Lisdexamfetamine—SLC6A3—central nervous system—brain cancer	0.00561	0.0138	CbGeAlD
Lisdexamfetamine—Decreased appetite—Lomustine—brain cancer	0.0056	0.0102	CcSEcCtD
Lisdexamfetamine—SLC6A3—cerebellum—brain cancer	0.00549	0.0135	CbGeAlD
Lisdexamfetamine—Diplopia—Carmustine—brain cancer	0.00521	0.00948	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Lomustine—brain cancer	0.0051	0.00928	CcSEcCtD
Lisdexamfetamine—Weight increased—Hydroxyurea—brain cancer	0.00507	0.00923	CcSEcCtD
Lisdexamfetamine—Diplopia—Temozolomide—brain cancer	0.00504	0.00916	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—OTX2—brain cancer	0.00503	0.112	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—endocrine gland—brain cancer	0.00503	0.0124	CbGeAlD
Lisdexamfetamine—SLC6A2—head—brain cancer	0.00496	0.0122	CbGeAlD
Lisdexamfetamine—Affect lability—Temozolomide—brain cancer	0.00496	0.00902	CcSEcCtD
Lisdexamfetamine—Nervousness—Procarbazine—brain cancer	0.00487	0.00887	CcSEcCtD
Lisdexamfetamine—Tremor—Procarbazine—brain cancer	0.0047	0.00855	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Hydroxyurea—brain cancer	0.0047	0.00855	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.00453	0.00825	CcSEcCtD
Lisdexamfetamine—SLC6A2—central nervous system—brain cancer	0.00453	0.0112	CbGeAlD
Lisdexamfetamine—SLC6A3—brain—brain cancer	0.00446	0.011	CbGeAlD
Lisdexamfetamine—Hallucination—Hydroxyurea—brain cancer	0.00444	0.00807	CcSEcCtD
Lisdexamfetamine—Convulsion—Procarbazine—brain cancer	0.00435	0.00791	CcSEcCtD
Lisdexamfetamine—Hypertension—Procarbazine—brain cancer	0.00433	0.00788	CcSEcCtD
Lisdexamfetamine—Anxiety—Procarbazine—brain cancer	0.00426	0.00774	CcSEcCtD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—brain cancer	0.00418	0.0931	CbGpPWpGaD
Lisdexamfetamine—Dry mouth—Procarbazine—brain cancer	0.00418	0.0076	CcSEcCtD
Lisdexamfetamine—Vomiting—Lomustine—brain cancer	0.0041	0.00746	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Temozolomide—brain cancer	0.00401	0.00729	CcSEcCtD
Lisdexamfetamine—Depression—Carmustine—brain cancer	0.004	0.00729	CcSEcCtD
Lisdexamfetamine—Tachycardia—Procarbazine—brain cancer	0.00399	0.00727	CcSEcCtD
Lisdexamfetamine—Weight increased—Temozolomide—brain cancer	0.00396	0.00721	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Procarbazine—brain cancer	0.00396	0.0072	CcSEcCtD
Lisdexamfetamine—Weight decreased—Temozolomide—brain cancer	0.00394	0.00717	CcSEcCtD
Lisdexamfetamine—Anorexia—Procarbazine—brain cancer	0.0039	0.0071	CcSEcCtD
Lisdexamfetamine—Depression—Temozolomide—brain cancer	0.00387	0.00704	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.00385	0.007	CcSEcCtD
Lisdexamfetamine—Nausea—Lomustine—brain cancer	0.00383	0.00697	CcSEcCtD
Lisdexamfetamine—Insomnia—Procarbazine—brain cancer	0.0037	0.00674	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—GLI2—brain cancer	0.00367	0.0818	CbGpPWpGaD
Lisdexamfetamine—Hepatobiliary disease—Temozolomide—brain cancer	0.00367	0.00668	CcSEcCtD
Lisdexamfetamine—Somnolence—Procarbazine—brain cancer	0.00364	0.00662	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Etoposide—brain cancer	0.00363	0.0066	CcSEcCtD
Lisdexamfetamine—SLC6A2—brain—brain cancer	0.0036	0.00886	CbGeAlD
Lisdexamfetamine—Hallucination—Carmustine—brain cancer	0.00359	0.00653	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Procarbazine—brain cancer	0.00356	0.00648	CcSEcCtD
Lisdexamfetamine—Fatigue—Procarbazine—brain cancer	0.00353	0.00642	CcSEcCtD
Lisdexamfetamine—Constipation—Procarbazine—brain cancer	0.0035	0.00637	CcSEcCtD
Lisdexamfetamine—Hepatitis—Temozolomide—brain cancer	0.00348	0.00634	CcSEcCtD
Lisdexamfetamine—Visual impairment—Carmustine—brain cancer	0.00347	0.00632	CcSEcCtD
Lisdexamfetamine—Hallucination—Temozolomide—brain cancer	0.00347	0.00631	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—brain cancer	0.00345	0.0769	CbGpPWpGaD
Lisdexamfetamine—Eye disorder—Carmustine—brain cancer	0.00337	0.00613	CcSEcCtD
Lisdexamfetamine—Convulsion—Hydroxyurea—brain cancer	0.00336	0.00612	CcSEcCtD
Lisdexamfetamine—Visual impairment—Temozolomide—brain cancer	0.00336	0.00611	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Temozolomide—brain cancer	0.00329	0.00599	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00328	0.00597	CcSEcCtD
Lisdexamfetamine—Eye disorder—Temozolomide—brain cancer	0.00326	0.00592	CcSEcCtD
Lisdexamfetamine—Urticaria—Procarbazine—brain cancer	0.00325	0.00592	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Procarbazine—brain cancer	0.00324	0.00589	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Temozolomide—brain cancer	0.00323	0.00588	CcSEcCtD
Lisdexamfetamine—Mental disorder—Carmustine—brain cancer	0.00316	0.00575	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Temozolomide—brain cancer	0.00315	0.00573	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Temozolomide—brain cancer	0.00314	0.00571	CcSEcCtD
Lisdexamfetamine—Malnutrition—Carmustine—brain cancer	0.00314	0.00571	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Hydroxyurea—brain cancer	0.00311	0.00565	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Etoposide—brain cancer	0.00308	0.0056	CcSEcCtD
Lisdexamfetamine—Skin disorder—Hydroxyurea—brain cancer	0.00308	0.0056	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Etoposide—brain cancer	0.00306	0.00557	CcSEcCtD
Lisdexamfetamine—Mental disorder—Temozolomide—brain cancer	0.00305	0.00555	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Etoposide—brain cancer	0.00304	0.00554	CcSEcCtD
Lisdexamfetamine—Malnutrition—Temozolomide—brain cancer	0.00303	0.00552	CcSEcCtD
Lisdexamfetamine—Anorexia—Hydroxyurea—brain cancer	0.00302	0.0055	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Procarbazine—brain cancer	0.00302	0.00549	CcSEcCtD
Lisdexamfetamine—Vision blurred—Carmustine—brain cancer	0.00296	0.00538	CcSEcCtD
Lisdexamfetamine—Tremor—Carmustine—brain cancer	0.00294	0.00535	CcSEcCtD
Lisdexamfetamine—Asthenia—Procarbazine—brain cancer	0.00294	0.00534	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Etoposide—brain cancer	0.00294	0.00534	CcSEcCtD
Lisdexamfetamine—Agitation—Carmustine—brain cancer	0.00288	0.00525	CcSEcCtD
Lisdexamfetamine—Vision blurred—Temozolomide—brain cancer	0.00286	0.0052	CcSEcCtD
Lisdexamfetamine—Tremor—Temozolomide—brain cancer	0.00284	0.00517	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Hydroxyurea—brain cancer	0.00282	0.00514	CcSEcCtD
Lisdexamfetamine—Somnolence—Hydroxyurea—brain cancer	0.00282	0.00513	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Procarbazine—brain cancer	0.0028	0.0051	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Hydroxyurea—brain cancer	0.00279	0.00508	CcSEcCtD
Lisdexamfetamine—Agitation—Temozolomide—brain cancer	0.00279	0.00507	CcSEcCtD
Lisdexamfetamine—Angioedema—Temozolomide—brain cancer	0.00277	0.00504	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Hydroxyurea—brain cancer	0.00275	0.00501	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00273	0.00498	CcSEcCtD
Lisdexamfetamine—Fatigue—Hydroxyurea—brain cancer	0.00273	0.00497	CcSEcCtD
Lisdexamfetamine—Convulsion—Carmustine—brain cancer	0.00272	0.00495	CcSEcCtD
Lisdexamfetamine—Hypertension—Carmustine—brain cancer	0.00271	0.00493	CcSEcCtD
Lisdexamfetamine—Constipation—Hydroxyurea—brain cancer	0.00271	0.00493	CcSEcCtD
Lisdexamfetamine—Dizziness—Procarbazine—brain cancer	0.00271	0.00493	CcSEcCtD
Lisdexamfetamine—Palpitations—Temozolomide—brain cancer	0.00268	0.00488	CcSEcCtD
Lisdexamfetamine—Anxiety—Carmustine—brain cancer	0.00266	0.00485	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Etoposide—brain cancer	0.00264	0.0048	CcSEcCtD
Lisdexamfetamine—Convulsion—Temozolomide—brain cancer	0.00263	0.00478	CcSEcCtD
Lisdexamfetamine—Hypertension—Temozolomide—brain cancer	0.00262	0.00476	CcSEcCtD
Lisdexamfetamine—Eye disorder—Etoposide—brain cancer	0.0026	0.00474	CcSEcCtD
Lisdexamfetamine—Vomiting—Procarbazine—brain cancer	0.0026	0.00474	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Etoposide—brain cancer	0.00259	0.00471	CcSEcCtD
Lisdexamfetamine—Rash—Procarbazine—brain cancer	0.00258	0.0047	CcSEcCtD
Lisdexamfetamine—Dermatitis—Procarbazine—brain cancer	0.00258	0.00469	CcSEcCtD
Lisdexamfetamine—Anxiety—Temozolomide—brain cancer	0.00257	0.00468	CcSEcCtD
Lisdexamfetamine—Headache—Procarbazine—brain cancer	0.00256	0.00467	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00256	0.00467	CcSEcCtD
Lisdexamfetamine—Dry mouth—Temozolomide—brain cancer	0.00252	0.00459	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Etoposide—brain cancer	0.00252	0.00458	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Etoposide—brain cancer	0.00251	0.00457	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Hydroxyurea—brain cancer	0.0025	0.00456	CcSEcCtD
Lisdexamfetamine—Tachycardia—Carmustine—brain cancer	0.0025	0.00455	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SHH—brain cancer	0.0025	0.0556	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Temozolomide—brain cancer	0.00247	0.0045	CcSEcCtD
Lisdexamfetamine—Anorexia—Carmustine—brain cancer	0.00244	0.00444	CcSEcCtD
Lisdexamfetamine—Nausea—Procarbazine—brain cancer	0.00243	0.00442	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Temozolomide—brain cancer	0.00243	0.00442	CcSEcCtD
Lisdexamfetamine—Skin disorder—Temozolomide—brain cancer	0.0024	0.00437	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Temozolomide—brain cancer	0.00239	0.00435	CcSEcCtD
Lisdexamfetamine—Anorexia—Temozolomide—brain cancer	0.00236	0.00429	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Hydroxyurea—brain cancer	0.00233	0.00425	CcSEcCtD
Lisdexamfetamine—Insomnia—Carmustine—brain cancer	0.00232	0.00422	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Carmustine—brain cancer	0.00228	0.00416	CcSEcCtD
Lisdexamfetamine—Somnolence—Carmustine—brain cancer	0.00228	0.00414	CcSEcCtD
Lisdexamfetamine—Asthenia—Hydroxyurea—brain cancer	0.00227	0.00414	CcSEcCtD
Lisdexamfetamine—Insomnia—Temozolomide—brain cancer	0.00224	0.00407	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Carmustine—brain cancer	0.00223	0.00405	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Carmustine—brain cancer	0.00221	0.00402	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Temozolomide—brain cancer	0.00221	0.00402	CcSEcCtD
Lisdexamfetamine—Somnolence—Temozolomide—brain cancer	0.0022	0.004	CcSEcCtD
Lisdexamfetamine—Constipation—Carmustine—brain cancer	0.00219	0.00399	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—GLI2—brain cancer	0.00219	0.0487	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Temozolomide—brain cancer	0.00218	0.00396	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Hydroxyurea—brain cancer	0.00217	0.00394	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Temozolomide—brain cancer	0.00215	0.00392	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Temozolomide—brain cancer	0.00214	0.00389	CcSEcCtD
Lisdexamfetamine—Fatigue—Temozolomide—brain cancer	0.00213	0.00388	CcSEcCtD
Lisdexamfetamine—Constipation—Temozolomide—brain cancer	0.00212	0.00385	CcSEcCtD
Lisdexamfetamine—Convulsion—Etoposide—brain cancer	0.0021	0.00383	CcSEcCtD
Lisdexamfetamine—Hypertension—Etoposide—brain cancer	0.00209	0.00381	CcSEcCtD
Lisdexamfetamine—Dizziness—Hydroxyurea—brain cancer	0.00209	0.00381	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—brain cancer	0.00206	0.0458	CbGpPWpGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00205	0.00373	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Carmustine—brain cancer	0.00202	0.00368	CcSEcCtD
Lisdexamfetamine—Vomiting—Hydroxyurea—brain cancer	0.00201	0.00367	CcSEcCtD
Lisdexamfetamine—Rash—Hydroxyurea—brain cancer	0.002	0.00364	CcSEcCtD
Lisdexamfetamine—Dermatitis—Hydroxyurea—brain cancer	0.002	0.00363	CcSEcCtD
Lisdexamfetamine—Headache—Hydroxyurea—brain cancer	0.00198	0.00361	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—brain cancer	0.00198	0.0036	CcSEcCtD
Lisdexamfetamine—Urticaria—Temozolomide—brain cancer	0.00197	0.00358	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Temozolomide—brain cancer	0.00196	0.00356	CcSEcCtD
Lisdexamfetamine—Tachycardia—Etoposide—brain cancer	0.00193	0.00352	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—brain cancer	0.00192	0.0035	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—brain cancer	0.00191	0.00348	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—brain cancer	0.00189	0.00344	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Carmustine—brain cancer	0.00189	0.00343	CcSEcCtD
Lisdexamfetamine—Nausea—Hydroxyurea—brain cancer	0.00188	0.00342	CcSEcCtD
Lisdexamfetamine—Asthenia—Carmustine—brain cancer	0.00184	0.00334	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Temozolomide—brain cancer	0.00182	0.00332	CcSEcCtD
Lisdexamfetamine—Asthenia—Temozolomide—brain cancer	0.00178	0.00323	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—brain cancer	0.00177	0.00321	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—brain cancer	0.00176	0.0032	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Carmustine—brain cancer	0.00175	0.00319	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—brain cancer	0.00172	0.00313	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—brain cancer	0.00171	0.00311	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—brain cancer	0.00171	0.00311	CcSEcCtD
Lisdexamfetamine—Dizziness—Carmustine—brain cancer	0.00169	0.00308	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—brain cancer	0.00169	0.00308	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Temozolomide—brain cancer	0.00169	0.00308	CcSEcCtD
Lisdexamfetamine—Dizziness—Temozolomide—brain cancer	0.00164	0.00298	CcSEcCtD
Lisdexamfetamine—Vomiting—Carmustine—brain cancer	0.00163	0.00296	CcSEcCtD
Lisdexamfetamine—Rash—Carmustine—brain cancer	0.00161	0.00294	CcSEcCtD
Lisdexamfetamine—Dermatitis—Carmustine—brain cancer	0.00161	0.00294	CcSEcCtD
Lisdexamfetamine—Headache—Carmustine—brain cancer	0.0016	0.00292	CcSEcCtD
Lisdexamfetamine—Vomiting—Temozolomide—brain cancer	0.00157	0.00286	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—brain cancer	0.00157	0.00286	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—brain cancer	0.00157	0.00285	CcSEcCtD
Lisdexamfetamine—Rash—Temozolomide—brain cancer	0.00156	0.00284	CcSEcCtD
Lisdexamfetamine—Dermatitis—Temozolomide—brain cancer	0.00156	0.00284	CcSEcCtD
Lisdexamfetamine—Headache—Temozolomide—brain cancer	0.00155	0.00282	CcSEcCtD
Lisdexamfetamine—Nausea—Carmustine—brain cancer	0.00152	0.00277	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—SHH—brain cancer	0.00149	0.0331	CbGpPWpGaD
Lisdexamfetamine—Nausea—Temozolomide—brain cancer	0.00147	0.00268	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—brain cancer	0.00146	0.00266	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—brain cancer	0.00142	0.00259	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—brain cancer	0.00135	0.00247	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—brain cancer	0.00131	0.00238	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—brain cancer	0.00126	0.00229	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—brain cancer	0.00125	0.00227	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—brain cancer	0.00125	0.00227	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—brain cancer	0.00124	0.00226	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—STRADA—brain cancer	0.00121	0.0271	CbGpPWpGaD
Lisdexamfetamine—Nausea—Etoposide—brain cancer	0.00118	0.00214	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—ABR—brain cancer	0.000948	0.0211	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CCNE1—brain cancer	0.000784	0.0175	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000678	0.0151	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000471	0.0105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—VAV1—brain cancer	0.00045	0.01	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000404	0.009	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000317	0.00705	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—brain cancer	0.000305	0.0068	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTCH2—brain cancer	0.000293	0.00654	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—TRPC6—brain cancer	0.000289	0.00644	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—S100A10—brain cancer	0.000281	0.00625	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	0.000258	0.00576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OR14C36—brain cancer	0.000257	0.00573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OR4C12—brain cancer	0.000257	0.00573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—RELA—brain cancer	0.000253	0.00564	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OR4C12—brain cancer	0.000234	0.00521	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OR14C36—brain cancer	0.000234	0.00521	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000217	0.00484	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—brain cancer	0.000174	0.00389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SHH—brain cancer	0.000151	0.00337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTCH2—brain cancer	0.000151	0.00335	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000146	0.00326	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTCH1—brain cancer	0.000143	0.00319	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SMO—brain cancer	0.000143	0.00319	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OR14C36—brain cancer	0.000138	0.00308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OR4C12—brain cancer	0.000138	0.00308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—brain cancer	0.000138	0.00307	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ABR—brain cancer	0.00013	0.0029	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TRPC6—brain cancer	0.00013	0.00289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ABR—brain cancer	0.000118	0.00263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DTX2—brain cancer	0.000117	0.00261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTCH2—brain cancer	8.9e-05	0.00198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES5—brain cancer	8.62e-05	0.00192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STRADA—brain cancer	8.36e-05	0.00186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRPC6—brain cancer	8.24e-05	0.00183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SHH—brain cancer	7.76e-05	0.00173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRPC6—brain cancer	7.48e-05	0.00167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SMO—brain cancer	7.35e-05	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTCH1—brain cancer	7.35e-05	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ABR—brain cancer	6.98e-05	0.00155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLI2—brain cancer	6.74e-05	0.0015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	6.62e-05	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLI1—brain cancer	6.34e-05	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—VAV1—brain cancer	6.17e-05	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SUFU—brain cancer	6.01e-05	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GFAP—brain cancer	5.8e-05	0.00129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—VAV1—brain cancer	5.6e-05	0.00125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY1—brain cancer	5.5e-05	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DLL1—brain cancer	5.39e-05	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SHH—brain cancer	4.58e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRPC6—brain cancer	4.42e-05	0.000984	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTCH1—brain cancer	4.34e-05	0.000968	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMO—brain cancer	4.34e-05	0.000968	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—brain cancer	3.92e-05	0.000873	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—brain cancer	3.56e-05	0.000793	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH2—brain cancer	3.47e-05	0.000774	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VAV1—brain cancer	3.31e-05	0.000738	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—brain cancer	2.85e-05	0.000634	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—brain cancer	2.76e-05	0.000614	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRA—brain cancer	2.71e-05	0.000604	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPP1—brain cancer	2.63e-05	0.000586	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—brain cancer	2.5e-05	0.000558	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS2—brain cancer	2.38e-05	0.00053	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—brain cancer	2.1e-05	0.000468	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—brain cancer	2.1e-05	0.000468	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—brain cancer	1.92e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—brain cancer	1.64e-05	0.000366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—brain cancer	1.63e-05	0.000364	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—brain cancer	1.48e-05	0.00033	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—brain cancer	1.44e-05	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—brain cancer	1.43e-05	0.000318	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—brain cancer	1.26e-05	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—brain cancer	1.24e-05	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—brain cancer	1.16e-05	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—brain cancer	1.13e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—brain cancer	9.5e-06	0.000212	CbGpPWpGaD
